Guardant Health, Inc. (GH) — AI 주식 분석

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

GH는 Guardant Health, Inc.를 나타내며, 현재 주가는 $155.87입니다. 성장 잠재력, 재무 건전성, 모멘텀에서 34/100(신중)으로 평가됩니다.

가던트 헬스는 정밀 종양학 분야의 선두 기업으로, 암 조기 발견 및 치료 모니터링을 위한 혈액 기반 게놈 검사(액체생검)를 제공합니다.

주요 정보: 가격: $155.87 일일 변동: +0.56% 시가총액: $20.7B 애널리스트 목표가: $129.57 목표가 상승여력: -16.9% AI 점수: 34/100 거래소: NASDAQ

기업 개요

요약:

Guardant Health, Inc. is a 정밀 종양학 company focused on developing and commercializing non-invasive cancer tests. Their 액체생검 technology aims to transform cancer care through early detection, treatment selection, and recurrence monitoring.

Guardant Health is a 정밀 종양학 leader, providing 액체생검 tests and 데이터 분석 to improve cancer patient outcomes. Their innovative Guardant360 and LUNAR assays, coupled with strategic bio제약 partnerships, position them for growth in the expanding market for non-invasive cancer diagnostics.

GH는 무엇을 하는 회사인가요?

Guardant Health, Inc., 년에 설립된 2011 and 에 본사를 둔 Redwood City, California, is a 정밀 종양학 company revolutionizing cancer treatment through non-invasive diagnostics. The company's core technology centers around liquid biopsies, which analyze circulating tumor DNA (ctDNA) in blood samples to provide comprehensive genomic information about a patient's cancer. Their flagship product, Guardant360, is used for advanced-stage cancer patients to guide treatment decisions by identifying actionable mutations. Guardant Health also offers GuardantOMNI, another 액체생검 test for advanced stage cancer, and GuardantINFORM, a research platform that 레버리지s a clinical-genomic 액체생검 dataset. Furthermore, they are developing the LUNAR-2 test for early detection of colorectal cancer in asymptomatic individuals. Guardant Health's products and services extend to bio제약 companies, offering companion diagnostic development, 임상시험 support, and regulatory approval assistance. With a focus on innovation and data-driven insights, Guardant Health aims to transform cancer care by enabling earlier and more precise interventions.

GH의 투자 테제는 무엇인가요?

Guardant Health presents a notable market position within the rapidly growing 정밀 종양학 market. The company's 액체생검 technology offers a non-invasive alternative to traditional tissue biopsies, providing valuable genomic information for treatment selection and monitoring. Key value drivers include the increasing adoption of Guardant360 in advanced-stage cancer, the potential of LUNAR-2 in early cancer detection, and partnerships with bio제약 companies for companion diagnostic development. The company's 매출총이익률 of 64.5% indicates strong 가격 결정력. However, the negative 순이익률 of -42.4% and negative 잉여현금흐름 of $-0.08B highlight the need for continued 매출 성장 and cost management. The company's beta of 1.65 suggests higher 변동성 compared to the overall market.

GH는 어떤 산업에서 운영되고 있나요?

Guardant Health operates in the dynamic and rapidly evolving 정밀 종양학 market. The industry is driven by advancements in genomic sequencing, increasing demand for personalized medicine, and the growing prevalence of cancer. The 액체생검 market is experiencing significant growth, offering a less invasive and more convenient alternative to traditional tissue biopsies. Guardant Health competes with companies like Exact Sciences Corporation (EXAS) in the cancer diagnostics space. The company's focus on innovation, 데이터 분석, and 전략적 파트너십s positions it to capitalize on the growing demand for 정밀 종양학 solutions.

Medical - Diagnostics & Research

헬스케어

GH의 성장 기회는 무엇인가요?

Expansion of LUNAR-2 into Early Cancer Detection: Guardant Health is developing the LUNAR-2 test for early detection of colorectal cancer in asymptomatic individuals. The market for early cancer detection is estimated to be substantial, with a significant unmet need for non-invasive screening methods. Successful commercialization of LUNAR-2 could drive significant 매출 성장 for Guardant Health, with potential FDA approval expected within the next 2-3 years.
Increased Adoption of Guardant360 in Advanced-Stage Cancer: Guardant360 is already a leading 액체생검 test for advanced-stage cancer, but there is still significant room for growth in terms of market penetration. As more oncologists and patients become aware of the benefits of liquid biopsies, adoption of Guardant360 is expected to increase. Guardant Health can further drive adoption through targeted marketing, educational initiatives, and expansion of its sales force.
Companion Diagnostic Development with Bio제약 Companies: Guardant Health partners with bio제약 companies to develop companion diagnostics that can identify patients who are most likely to benefit from specific cancer therapies. This is a growing market, as 제약 companies increasingly rely on precision medicine to improve the efficacy of their drugs. Guardant Health's expertise in 액체생검 and genomic analysis makes it a valuable partner for bio제약 companies.
지역 확장 into International Markets: Guardant Health currently generates most of its 매출 in the United States. Expanding into international markets, such as Europe and Asia, represents a significant growth opportunity. These markets have a large and growing population of cancer patients, and there is increasing demand for advanced diagnostic technologies. Guardant Health can 레버리지 its existing products and services to enter these markets, either through direct sales or partnerships with local distributors.
Development of New 액체생검 Tests for Other Cancer Types: Guardant Health is continuously investing in 연구개발(R&D) to expand its portfolio of 액체생검 tests. This includes developing new tests for other cancer types, such as lung cancer, breast cancer, and prostate cancer. By expanding its product portfolio, Guardant Health can address a broader range of patient needs and further solidify its position as a leader in the 정밀 종양학 market.

시가총액 $11.13B reflects investor confidence in Guardant Health's growth potential in the 정밀 종양학 market.
매출총이익률 of 64.5% demonstrates strong 가격 결정력 and efficient cost management in the development and commercialization of 액체생검 tests.
Negative 순이익률 of -42.4% indicates ongoing investments in 연구개발(R&D) and commercial expansion.
잉여현금흐름 of $-0.08B suggests a need for continued monitoring of cash burn and potential future financing needs.
Guardant Health is developing LUNAR-2 test for the early detection of colorectal cancer, expanding its market opportunity beyond advanced-stage cancer.

GH는 어떤 제품과 서비스를 제공하나요?

Develop and commercialize 액체생검 tests for cancer detection and monitoring.
Provide genomic information to guide treatment decisions for advanced-stage cancer patients.
Offer the Guardant360 test, a comprehensive 액체생검 for advanced cancer.
Develop the LUNAR-2 test for early detection of colorectal cancer.
Partner with bio제약 companies for companion diagnostic development.
Offer GuardantINFORM, a research platform with clinical-genomic data.
Provide development services, including clinical study setup and regulatory approval support.

GH는 어떻게 수익을 창출하나요?

Direct sales of 액체생검 tests to oncologists and hospitals.
Partnerships with bio제약 companies for companion diagnostic development.
Data licensing and analytics services through the GuardantINFORM platform.
Reimbursement from insurance companies and government payers for diagnostic testing.

Oncologists and other healthcare providers who treat cancer patients.
Hospitals and cancer centers that offer diagnostic testing services.
Bio제약 companies developing cancer therapies.
Researchers and academic institutions studying cancer genomics.

Proprietary 액체생검 technology with high sensitivity and specificity.
Extensive clinical-genomic database that provides valuable insights for cancer research and treatment.
Strong relationships with leading oncologists and cancer centers.
전략적 파트너십s with bio제약 companies for companion diagnostic development.

GH 주가를 상승시킬 수 있는 요인은 무엇인가요?

Upcoming: Potential FDA approval of LUNAR-2 for early colorectal cancer detection.
Ongoing: Increasing adoption of Guardant360 by oncologists for treatment decisions.
Ongoing: Expansion of partnerships with bio제약 companies for companion diagnostic development.
Ongoing: Publication of clinical data supporting the efficacy of Guardant Health's 액체생검 tests.

GH의 주요 리스크는 무엇인가요?

Potential: Competition from other diagnostic companies offering similar 액체생검 tests.
Potential: Changes in reimbursement policies that could reduce 매출 from diagnostic testing.
Potential: Technological advancements that could render existing products obsolete.
Ongoing: Regulatory risks associated with the development and commercialization of diagnostic tests.
Ongoing: The company's negative 순이익률 and 잉여현금흐름 necessitate careful financial management.

GH의 핵심 강점은 무엇인가요?

Leading position in the 액체생검 market.
Proprietary technology and extensive clinical-genomic database.
Strong partnerships with bio제약 companies.
Experienced 경영진.

GH의 약점은 무엇인가요?

Negative 순이익률 and 잉여현금흐름.
Reliance on reimbursement from insurance companies.
Competition from other diagnostic companies.
Regulatory risks associated with diagnostic testing.

GH에게 어떤 기회가 있나요?

Expansion into early cancer detection with LUNAR-2.
Increased adoption of Guardant360 in advanced-stage cancer.
지역 확장 into international markets.
Development of new 액체생검 tests for other cancer types.

GH는 어떤 위협에 직면하고 있나요?

Competition from established diagnostic companies and new entrants.
Technological advancements that could render existing products obsolete.
Changes in reimbursement policies that could reduce 매출.
경기 침체 that could reduce demand for diagnostic testing.

GH의 경쟁사는 누구인가요?

Exact Sciences Corporation — Focuses on early cancer detection with Cologuard. — (EXAS)
Viatris Inc. — Global 제약 company with a broad portfolio of products. — (VTRS)
Ascendis Pharma A/S — Bio제약 company focused on endocrine therapies. — (ASND)
BridgeBio Pharma, Inc. — Develops therapies for genetic diseases. — (BBIO)
Ionis 제약s, Inc. — Focuses on RNA-targeted therapeutics. — (IONS)

목표 주가

Analyst Consensus Target: $129.57
Current price: $88.50
Implied Upside: +46.4%

회사 프로필

CEO: Helmy Eltoukhy
Headquarters: Palo Alto, CA, US
Employees: 1,999
Founded: 2018

AI 인사이트

Guardant Health, Inc. is a 정밀 종양학 company that provides blood tests, data sets, and analytics. Their products include 액체생검-based tests for advanced stage cancer and development services for bio제약 companies.

질문 및 답변

What does Guardant Health, Inc. do?

Guardant Health, Inc. is a 정밀 종양학 company that develops and commercializes 액체생검 tests for cancer detection, treatment selection, and monitoring. Their flagship product, Guardant360, is used to guide treatment decisions for advanced-stage cancer patients by identifying actionable mutations. The company is also developing LUNAR-2 for early detection of colorectal cancer. Guardant Health partners with bio제약 companies to develop companion diagnostics and offers 데이터 분석 services through its GuardantINFORM platform. Their business model revolves around direct sales of tests, partnerships, and data licensing.

What do analysts say about GH stock?

애널리스트 컨센서스 on Guardant Health (GH) stock is generally positive, reflecting optimism about the company's growth prospects in the 정밀 종양학 market. Key 밸류에이션 metrics include 시가총액 and 매출 성장. Analysts closely monitor the adoption rate of Guardant360, the progress of LUNAR-2, and the company's partnerships with bio제약 companies. Growth considerations include market penetration, 지역 확장, and the development of new 액체생검 tests. However, analysts also acknowledge the risks associated with competition, reimbursement policies, and regulatory hurdles.

What are the main risks for GH?

The main risks for Guardant Health (GH) include competition from other diagnostic companies, potential changes in reimbursement policies that could reduce 매출, and technological advancements that could render existing products obsolete. Regulatory risks associated with the development and commercialization of diagnostic tests also pose a challenge. Additionally, the company's negative 순이익률 and 잉여현금흐름 necessitate careful financial management. The success of LUNAR-2 is also critical, and any delays or setbacks in its development could negatively impact the company's growth prospects.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.